January Employee Spotlight – John Pavlovich

January Employee Spotlight – John Pavlovich

 

At our January CMT Solutions company meeting, our employee spotlight featured our CFO/COO John Pavlovich! John shared with the company his love for hiking outdoors, spending time with his family, and his very first job was weeding a nursery garden that was out of business! John, you sure have come a long way, CMT Solutions is so proud to have you head up our operations. With your leadership, we are able to serve 100,000 patients and we keep growing every day -helping patients, physicians, and laboratories.

 

CMT Solutions Orlando Operations HubCenter Expands

CMT Solutions is proud to see our Orlando Operations HubCenter grow! We recently expanded with an additional 3,000 square feet.

 

“This allows us to increase in the coming months up to 30 Patient Access Specialists in the Orlando office, further helping physicians and their patients treat their condition or disease through genetic testing” says John Pavlovich, CMT’s CFO and COO.

 

CMT first moved into their existing office back in May 2019, and this space provides room for expansion as the company enrolls new physician offices, partners with additional laboratories, and launches new services. The expansion will provide both work and meeting space as the team is currently outgrowing their initial surroundings.

 

This news continues CMT’s long term strategy of building an Orlando based operations team, in a location known for having deep experience in healthcare administration. “We continue to attract experienced team members and are always looking to add quality people who are a great fit for our company.”

CMT Solutions achieves milestone event to close out 2019

CMT Solutions achieved a milestone event to close out 2019, we received our 100,000 patient service case.  Achieving 100,000 patients is a major milestone for the company. In less than two years of being in business, we have helped 100,000 patients get access to the testing that they need, helping them better manage their condition or disease. In 2019, we have launched new services, including genetic counseling and benefits investigations.

Congratulations to the entire team and we look forward to the next milestone in 2020.

CMT Solutions Celebrates Breast Cancer Awareness in October

 

The employees at CMT Solutions took time to support the breast cancer community and each other by raising awareness about the disease, it’s reach and impact.

There are many of us who have been affected by breast cancer, whether it is knowing someone who has fought the disease, being diagnosed ourselves, or being active in the prevention and screening awareness. Early detection can protect ourselves from breast cancer. Stage 0 and Stage 1 breast cancer have over a 99% 5-year survival rate. Everyone should assess their own personal risk of breast cancer. If you have had a family member that had a certain type of cancer, you may have an elevated risk for yourself. Have a conversation with your healthcare provider, and if your risk is elevated especially, consider diagnostic testing to assess your risk.

Here at CMT, we work with physicians and laboratories who order and perform diagnostic testing for breast cancer and oncology. We recognize the importance of this test to patients, their family, and the community. We will continue to perform our jobs at the highest level of service and dedication to our partners and clients.

The Emerging Use By Commercial Payers Of Third-Party Lab Benefit Managers For Genetic Testing

This was originally published on Health Affairs on October 23rd, 2019, written by Kathryn A. Phillips, Patricia A. Deverka.

Our newly released study examines the increasingly important but poorly understood role of Lab Benefit Managers (LBMs).Pharmaceutical Benefit Managers (PBMs) have generated widespread attention (often negative), but little attention has been paid to the rapid growth of LBMs. LBMs now manage genetic test benefits for hundreds of millions of enrollees and three of the four largest health plans in the U.S. use LBMs to manage genetic testing. These third party benefit managers are changing clinical and lab practice in significant ways. For example, some LBMs require prior authorization for all genetic tests, which has important implications for patients and providers, and some develop coverage policies on behalf of payers, thus changing the nature of coverage policy development in the U.S. 

This is the first study to our knowledge to examine the growth and role of LBMs. We describe the LBM landscape including the major players as well as the types of services LBMs offer to providers and labs on behalf of payers. Next, we attempt to apply lessons learned from recent observations regarding PBMs to LBMs in the hopes of avoiding some of the potential negative consequences of introducing misaligned incentives among patients, clinicians, labs and insurers. While the LBM business model is distinct from PBMs, it is instructive to look more closely at the current reach of LBMs to see how the use of intermediaries might affect genetic test access, costs, and utilization over time. Finally, we outline trends to watch to develop transparent, objective evidence about the impact of LBMs on patient outcomes, and to assess trade-offs between benefits and harms from tighter utilization management practices.

This article was from the Health Affairs Blog: https://www.healthaffairs.org/do/10.1377/hblog20191021.563154/full/